Europe Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size to Reach $3.2 Billion by 2035

Europe dipeptidyl peptidase 4 (DPP-4) inhibitors market size reached $2.3 billion in 2025 and is projected to expand to $3.2 billion by 2035, growing at a CAGR of 3.7% during the forecast period (2026–2035). Market growth is supported by increasing prevalence of type 2 diabetes, aging population demographics, and continued use of oral antidiabetic combination therapies.

Browse the full report description of “European Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size, Share & Trends Analysis Report by Drug Type (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/europe-dipeptidyl-peptidase-4-inhibitors-market

Key Market Drivers

• Rising prevalence of type 2 diabetes across European populations.
  • Increasing geriatric population requiring glucose-lowering therapies.
  • Continued physician preference for oral antidiabetic agents.
  • Growing use of fixed-dose combination diabetes treatments.
  • Expanding screening and early diagnosis programs.

Regional Analysis

Europe remains a significant market for DPP-4 inhibitors due to established diabetes treatment guidelines and universal healthcare systems supporting prescription access. Germany represents one of the largest pharmaceutical markets in Europe, with high diagnosed diabetes prevalence and reimbursement coverage through statutory health insurance, enabling sustained demand for oral antidiabetic drugs. In the UK, the National Health Service (NHS) follows NICE guidelines that include DPP-4 inhibitors as therapeutic options for patients inadequately controlled on metformin, particularly where weight neutrality or hypoglycemia risk considerations apply. Across Europe, increasing obesity rates and sedentary lifestyles contribute to growing type 2 diabetes incidence, supporting continued prescription volumes of DPP-4 inhibitors despite competition from newer drug classes such as SGLT2 inhibitors and GLP-1 receptor agonists.

Competitive Landscape

Key companies operating in the Europe dipeptidyl peptidase 4 (DPP-4) inhibitors market include Merck & Co., Novartis, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Takeda Pharmaceutical Company, Pfizer Inc., and Sanofi. These companies market DPP-4 inhibitors either as monotherapies or in fixed-dose combinations and maintain distribution networks across major European markets.

Recent Market Developments

• In July 2025, Azurity Pharmaceuticals announced the availability of BRYNOVIN (sitagliptin) oral solution, an oral liquid DPP-4 inhibitor indicated as an adjunct to diet and exercise for type 2 diabetes mellitus. Although approved by the U.S. FDA, sitagliptin is widely used in Europe under similar indications.

• In 2025, the European Medicines Agency confirmed that Sitagliptin/Metformin Hydrochloride Accord—containing the DPP-4 inhibitor sitagliptin—was no longer authorised in the EU. The product’s regulatory status update reflects shifts in the availability of sitagliptin-containing DPP-4 inhibitor therapies in European markets.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By drug type
• Region Covered-
  • Europe

Competitive Landscape- Merck & Co., Novartis, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Takeda Pharmaceutical Company, Pfizer Inc., and Sanofi.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Europe Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Report Segment

By drug type

• Sitagliptin
• Vildagliptin
• Saxagliptin
• Linagliptin 
• Gemigliptin 
• Anagliptin
• Teneligliptin 
• Others

Europe Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Report Segment by Region

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/europe-dipeptidyl-peptidase-4-inhibitors-market